Effectiveness of an add-on treatment with the homeopathic medication SilAtro-5-90 in recurrent tonsillitis: An international, pragmatic, randomized, controlled clinical trial

Complement Ther Clin Pract. 2017 Aug:28:181-191. doi: 10.1016/j.ctcp.2017.05.005. Epub 2017 May 22.


Objective: To investigate the effectiveness and safety of the homeopathic product SilAtro-5-90 in recurrent tonsillitis.

Methods: In this international, pragmatic, controlled clinical trial, 256 patients (6-60 years) with moderate recurrent tonsillitis were randomized to receive either SilAtro-5-90 in addition to standard symptomatic treatment, or to receive standard treatment only. The primary outcome was the mean time period between consecutive acute throat infections (ATI) within 1 year (analyzed via repeated events analysis).

Results: During the evaluation year, the risk of getting an ATI was significantly lower (hazard ratio: 0.45, proportional means model, p = 0.0002, ITT) with SilAtro-5-90 compared to control. Tonsillitis-specific symptoms were significantly reduced (p < 0.0001, ITT) and the need of antibiotics to treat acute throat infections (p = 0.0008; ITT) decreased. 3 non-serious adverse drug reactions were reported for SilAtro-5-90.

Conclusions: An integrative treatment approach where SilAtro-5-90 is given alongside mainstream symptomatic treatment may bring therapeutic benefit to patients suffering from recurrent tonsillitis.

Trial registration: ISRCTN registry: Registration number ISRCTN19016626, registered 23 January 2013.

Keywords: Acute throat infection; Homeopathy; Randomized controlled trial; Recurrent tonsillitis; SilAtro-5-90; Tonsilotren.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Communication
  • Female
  • Homeopathy*
  • Humans
  • Male
  • Materia Medica / therapeutic use*
  • Middle Aged
  • Pharyngitis
  • Recurrence
  • Tonsillitis / drug therapy*
  • Treatment Outcome
  • Young Adult


  • Anti-Bacterial Agents
  • Materia Medica